Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | RECQL | P46063 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900336 | 0.91 | MAP3K5 (0.62) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL5992796 | 0.91 | MAP3K5 (0.62) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL5991871 | 0.91 | HIF1AN (0.64) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL3900339 | 0.91 | MAP3K5 (0.62) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL14860651 | 0.91 | HIF1AN (0.64) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL14860649 | 0.91 | HIF1AN (0.64) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL683937 | 0.89 | ITGB2 (0.58) | ALDH1A1MAPTLMNAPOLBRAB9A | |
| SCHEMBL14859645 | 0.88 | MAP3K5 (0.66) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL14859642 | 0.88 | MAP3K5 (0.66) | ALDH1A1MAPTLMNAPOLBMEN1 | |
| SCHEMBL3904831 | 0.88 | MEN1 (0.54) | ALDH1A1MAPTLMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10239871-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239871-B2 | Compounds and methods for regulating integrins | ITGA2, ITGB2, ITGA2B | ALDH1A1 1927/4885MAPT 4654/4885LMNA 1434/4885 |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | ALDH1A1 473/4885MAPT 4318/4885LMNA 3145/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | ALDH1A1 1927/4885MAPT 4654/4885LMNA 1434/4885 |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | ALDH1A1 1927/4885MAPT 4654/4885LMNA 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.